Skip to main content
KT

Kimia Therapeutics

Kimia Therapeutics develops a drug discovery platform that combines high-throughput precision chemistry, genome editing, and machine learning to create a detailed chemical atlas of druggable targets in oncology, immunology, and inflammation. This technology enables the rapid identification of therapeutic compounds and the generation of extensive datasets that inform drug design and optimization.

Berkeley, United StatesFounded 2023332K+ followers
Updated 20 months ago

Funding

$57.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

DCTC
Funding rounds are not available yet.

Founders

Product

Problem

Traditional drug discovery processes are slow and inefficient, often struggling to identify novel therapeutic compounds and druggable targets, particularly in complex diseases like cancer, immunological disorders, and inflammation. The vast chemical space and intricate biological interactions make it challenging to pinpoint effective drug candidates and optimize their design.

Solution

Kimia Therapeutics offers a drug discovery platform, ATLAS, that accelerates the identification of therapeutic compounds by creating a detailed chemical atlas of druggable space. ATLAS integrates active learning, automated synthesis, and high-throughput screening with machine learning to map the relationship between chemical structure and protein function at single-atom resolution. This approach enables the generation of billions of target-directed compounds on demand and the creation of extensive datasets, including proteomic and gene editing information, to ensure appropriate engagement of intracellular pathways. Machine learning algorithms interpret these datasets to reveal trends that guide chemical design and lead optimization, fundamentally transforming the landscape of drug discovery.

Target Audience

Kimia's primary customers are pharmaceutical companies and research institutions focused on discovering novel therapeutics for oncology, immunology, and inflammation.

Features

  • AcTive® Learning technology to accelerate drug discovery
  • Automated synthesis and high-throughput screening for rapid compound generation
  • Machine learning algorithms to identify therapeutic targets and corresponding drug molecules
  • Target-directed precision chemistry to access billions of compounds on demand
  • Proteomic and gene editing data integration to ensure appropriate engagement of intracellular pathways
  • Chemical atlas of druggable space mapping chemical structure to protein function at single-atom resolution
This profile is AI-generated and may contain inaccuracies.